Since αS acts in the nucleus to promote neurotoxicity, mostly by interfering with histone acetylation and HAT member activities, our findings suggest that the development of GCN5-dependent therapeutics might benefit PD and other synucleinopathy. This evidence concerns the gene TMPRSS11D and synucleinopathy.